



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE:+044-25267517/25270992, FAX:91-44-25231264, Email: info@bafnapharma.com, website: www.bafnapharma.com

October 3, 2017

To
BSE Limited
P J Towers, Dalal Street
Mumbai – 400 001

Dear Sir/Madam,

**Sub: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
– Summary of proceedings of the AGM held on September 30, 2017**

We enclose herewith the summary of the proceedings of 22nd Annual General Meeting of the Company held on September 30, 2017 at 2.00 P.M. and concluded at 3.00 P.M as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your kind information and records.

Thanking You,

Yours Faithfully,
For BAFNA PHARMACEUTICALS LIMITED



Paras Bafna
Director



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE:+044-25267517/25270992, FAX:91-44-25231264, Email: info@bafnapharma.com, website: www.bafnapharma.com

Summary of proceedings of Annual General Meeting held on September 30, 2017

The Annual General Meeting of the Company was held on September 30, 2017 at 2.00 P.M. at 147, Madhavaram Red Hills High Road, Grantlyon Village, Chennai – 600052. Mr. Bafna Mahaveerchand, Managing Director, was elected as Chairman of the meeting and conducted the proceedings of the meeting.

The Chairman after confirming that the quorum is present, called the meeting to order. Then, he introduced the Directors of the Company present in the dais. He also introduced Statutory Auditors and Secretarial Auditors of the Company. Then he delivered his speech.

The Chairman requested the members to take note that the Auditor's Report does not contain qualifications, observations or comments on financial transactions or matters, which have any adverse effect on the functioning of the company.

Then the Chairman invited comments and questions from the members. The queries /comments raised by them were clarified/answered/noted.

The Chairman informed the members about the remote e-Voting facility made available to the members from 26.09.2017 (09.00 AM) to 29.09.2017 (5.00 PM). Members who were present at the AGM and had not cast their votes electronically were provided an opportunity to cast their votes at the meeting.

The following items as set out in the Notice of AGM were transacted in the meeting:

1. Adoption of the financial statements of the Company for the year ended 31st March, 2017 including the audited Balance Sheet as at 31st March, 2017, the audited Statement of Profit and Loss for the year ended on that date, notes thereto, together with the reports of the Board of Directors and Auditors thereon.
2. Adoption of the Consolidated financial statements of the Company for the year ended 31st March, 2017 including the audited Balance Sheet as at 31st March, 2017, the audited Statement of Profit and Loss for the year ended on that date, notes thereto, together with the reports of the Board of Directors and Auditors thereon
3. Appointment of a Director in the place of Shri Bafna Mahaveer Chand (DIN: 01458211), who retires by rotation and being eligible, offers himself for re-appointment as a Director.
4. Appointment of a Director in the place of Shri Paras Bafna (DIN: 01933663), who retires by rotation and being eligible offers himself for re-appointment as a Director.



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE:+044-25267517/25270992, FAX:91-44-25231264, Email: info@bafnapharma.com, website: www.bafnapharma.com

5. Appointment of M/s. R Sathyanarayanan & Co., Chartered Accountants, Chennai (FRN: 003656S) as Statutory Auditors of the Company, in the place of retiring auditor M/s. Abhay Jain & Co, Chartered Accountants, Chennai.
6. To ratify Appointment & Remuneration of Cost Auditors.
7. To re-appoint Shri Bafna Mahaveer Chand (DIN: 01458211) as Managing Director of the Company for a period of Three (3) consecutive years.
8. To re-appoint Shri Paras Bafna (DIN: 01933663) as Whole time Director of the Company for a period of Three (3) consecutive years.

The Board of Directors had appointed Mr. Pankaj Mehta as the Scrutinizer to supervise the e -voting and ballot voting process.

The members then cast their votes on the ballot paper and deposited the same in the ballot box. The Chairman informed the members that the consolidated results of E-voting and Poll will be declared within 48 hours of conclusion of meeting and also be intimated to stock exchange and posted in the website of the company.

The Chairman thanked the members present and declared the meeting closed. The meeting concluded at 3.00 P.M.

For BAFNA PHARMACEUTICALS LIMITED

Paras Bafna
Director